All In Biotech

NDA 200738 · Bausch and Lomb

Lotemax

Loteprednol Etabonate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Dec 8, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Apr 15, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

16 Phase 3, 0 recruiting

FAERS reports

4,307

1,582 serious, 124 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 30, 2022.

LOTEMAX ® (loteprednol etabonate ophthalmic ointment) 0.5% ointment is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. LOTEMAX ointment is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. (1)

Mechanism: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor‑dependent modulation of inflammation are not clearly established. However, corticosteroids are thought to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LOTEMAX · LOTEPREDNOL ETABONATE 0.5% · OINTMENT, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain600
  • eye irritation483
  • off label use353
  • drug ineffective329
  • vision blurred312
  • ocular hyperaemia279
  • headache230
  • fatigue216
  • dry eye180
  • pain169
  • nausea168
  • eye swelling153

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200515
200622
200716
200833
200965
2010107
201177
2012137
201388
2014152
2015275
2016388
2017341
2018318
2019350
2020277
2021255
2022291
2023286
2024305
2025300
2026201

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lotemax (Loteprednol Etabonate)

2024 spending

$9.5M

Beneficiaries

13,977

25,078 claims

Per beneficiary

$683

$88.65 per unit

View as table
YearSpending
2020$32,882,502
2021$18,035,919
2022$12,204,111
2023$10,831,409
2024$9,542,146

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.